Children's Mercy Kansas City

SHARE @ Children's Mercy

Presentations

8-2024

Variation in Systemic Corticosteroid Prescribing During Asthma-Related Hospitalizations Across Children's Hospitals

Sian Best

Matt Hall

Jessica L. Bettenhausen

Shelby Chesbro

Nicholas Clark

See next page for additional authors

Let us know how access to this publication benefits you

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/presentations



Part of the Pediatrics Commons

Creators

Sian Best, Matt Hall, Jessica L. Bettenhausen, Shelby Chesbro, Nicholas Clark, Megan Collins, Adrienne DePorre, Jonathan Ermer, Bridgette Jones, Leah Jones, Jessica Markham, Elisha McCoy, Maria Newmaster, Laura Plencner, Henry T. Puls, Smit Shah, and Kathryn Kyler

Variation and Trends in Inpatient Systemic Corticosteroid Prescribing During Asthma-Related Hospitalizations Across Children's Hospitals

Siân Best, MD; Matt Hall, PhD; Jessica Bettenhausen, MD; Shelby Chesbro, MD; Nicholas Clark, MD; Megan Collins, MD, MPH; Adrienne DePorre, MD; Jonathan Ermer, MD; Bridgette L. Jones, MD, MSCR; Leah Jones, MD; Jessica Markham, MD, MSc; Elisha McCoy, MD; Maria Newmaster, MD; Laura Plencner, MD; Hank Puls, MD; Smit Shah, MD, MS; Kathryn E. Kyler, MD, MS

















Disclosures

• No financial relationships to disclose



Background

- Asthma is the third-leading cause of non-injury related hospitalization among children less than 15 years of age
- Systemic steroids are the mainstay of treatment



Dexamethasone in Asthma Care



Systematic reviews found dexamethasone to be non-inferior to prednisolone



Potential practical benefits with the use of dexamethasone



High-quality studies in the ED found no difference in hospitalization outcomes



Studies in hospitalized children found no difference in hospitalization outcomes



Little mention of dexamethasone in national guidelines





Study Questions

• What are the current prescribing practices for systemic steroids in pediatric acute asthma?

 Have there been any changes in prescribing practices since the publication of the Cochrane reviews?





Objectives

 To describe variability and trends in inpatient systemic corticosteroid prescribing during acute asthma exacerbation hospitalizations

• To determine differences in hospitalization outcomes between children prescribed dexamethasone versus prednisone/prednisolone





Study Design

 Multicenter, retrospective, cross-sectional study utilizing PHIS database from 2016-2023

Inclusion Criteria

- Children aged 2-18 years
- Primary discharge diagnosis of asthma exacerbation
- Prescribed one of the following steroids: dexamethasone, prednisone, prednisolone, methylprednisolone

Exclusion Criteria

- Transfers from outside facilities
- Diagnoses of bronchiolitis, bacterial pneumonia, COVID-19, complex chronic conditions
- Children receiving other steroids
- Severe illness: LOS > 5 days, mechanical ventilation, NIV, ECMO, or CPR





Outcomes

- Primary
 - Percentage of hospitalization encounters with any dexamethasone ordered/prescribed within a hospital-year

- Secondary
 - Readmission rates at 7 days and 30 days post-discharge
 - ED revisits at 7 days and 30 days post-discharge
 - Hospital LOS





Covariates

Demographic Variables

- Age
- Sex
- Race/ethnicity
- Primary insurance payor

Clinical Characteristics

- Illness severity
- PICU stay
- Admission source
- LOS






Statistical Analysis

- Hospitals were grouped into quintiles based on dexamethasone use
- Generalized estimating equations used to analyze the association of annual hospital level dexamethasone use with hospitalization outcomes
- Sub analysis performed to investigate hospitalization outcomes for encounters with dexamethasone only versus prednisone/prednisolone only






Cohort Description







Results - Trends in Steroid Use







Results -Hospital-Level Variation

- Proportion of hospitals prescribing dexamethasone for >80% of encounters increased from 7 hospitals to 25 hospitals in 2023
- Eight hospitals exhibited no change in prescribing practices
- Only four hospitals prescribed dexamethasone for <60% of asthma encounters in 2023



% Dexamethasone Use
<20%
20-40%
41-60%
61-80%
81-100%





Results – Dexamethasone & Hospitalization Outcomes

 No difference in readmission, ED revisits, or LOS across hospitals when grouped by dexamethasone-use quintiles

 No difference in readmission, ED revisits, or LOS in encounters only receiving dexamethasone versus only prednisone/prednisolone





Limitations

- Lack of patient- and provider-level characteristics
- Medication prescription details and discharge medication data
- Focus on children's hospitals
- Direct admissions included
- PICU versus floor steroid administration





Conclusions

Dexamethasone use is increasing during hospitalizations for acute asthma exacerbation

Substantial variability in steroid prescribing practices between hospitals

No differences in LOS, ED revisits or hospital readmission rates between dexamethasone versus prednisone/prednisolone





Future Directions/Next Steps

- Need for randomized controlled trials or comparative effectiveness studies assessing dexamethasone versus prednisone/prednisolone for hospitalized children
- Analysis of prescribing practices in the PICU versus general inpatient floors
- Dexamethasone dosing variability
- Potential updates to national guidelines and institution-specific practice pathways to decrease variability





References

- Cai KJ, Su SQ, Wang YG, Zeng YM. Dexamethasone Versus Prednisone or Prednisolone for Acute Pediatric Asthma Exacerbations in the Emergency Department: A Meta-Analysis. *Pediatr Emerg Care*. 2021;37(12):e1139. doi:10.1097/PEC.0000000000001926
- Hemani SA, Glover B, Ball S, et al. Dexamethasone Versus Prednisone in Children Hospitalized for Acute Asthma Exacerbations. *Hosp Pediatr*. 2021;11(11):1263-1272. doi:10.1542/hpeds.2020-004788
- Hoefgen ER, Huang B, Schuler CL, et al. Dexamethasone Versus Prednisone in Children Hospitalized With Asthma Exacerbation. *Hosp Pediatr*. 2022;12(3):325-335. doi:10.1542/hpeds.2021-006276
- Kirkland SW, Cross E, Campbell S, Villa-Roel C, Rowe BH. Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma. *Cochrane Database Syst Rev.* 2018;2018(6):CD012629. doi:10.1002/14651858.CD012629.pub2
- Normansell R, Kew KM, Mansour G. Different oral corticosteroid regimens for acute asthma. *Cochrane Database Syst Rev.* 2016;2016(5). doi:10.1002/14651858.cd011801.pub2
- Paniagua N, Lopez R, Muñoz N, et al. Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations. *J Pediatr*. 2017;191:190-196.e1. doi:10.1016/j.jpeds.2017.08.030
- Parikh K, Hall M, Mittal V, et al. Comparative Effectiveness of Dexamethasone versus Prednisone in Children Hospitalized with Asthma. *J Pediatr*. 2015;167(3):639-644.e1. doi:10.1016/j.jpeds.2015.06.038
- Qureshi F, Zaritsky A, Poirier MP. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. *J Pediatr*. 2001;139(1):20-26. doi:10.1067/mpd.2001.115021





Thank You!

- Kathryn E. Kyler, MD, MS
- Matt Hall, PhD
- Jessica Bettenhausen, MD
- Shelby Chesbro, MD
- Nicholas Clark, MD
- Megan Collins, MD, MPH
- Adrienne DePorre, MD
- Jonathan Ermer, MD

- Bridgette L. Jones, MD, MSCR
- Leah Jones, MD
- Jessica Markham, MD, MSc
- Elisha McCoy, MD
- Maria Newmaster, MD
- Laura Plencner, MD
- Hank Puls, MD
- Smit Shah, MD, MS





Siân Best, MD
Children's Mercy Kansas City
scbest@cmh.edu





Extra – Steroid Trends

	Overall	2016	2017	2018	2019	2020	2021	2022	2023	p (Trend)
Dexamethasone	74199 (60.3)	7567 (42.4)	8416 (49.6)	8917 (53)	9256 (58.6)	4402 (62.3)	9061 (67.8)	13566 (73.8)	13014 (77.5)	<.001
Methylprednisolone	30396 (24.7)	4618 (25.9)	4272 (25.2)	4269 (25.4)	3892 (24.6)	1768 (25)	3366 (25.2)	4482 (24.4)	3729 (22.2)	<.001
Prednisolone/ Prednisone	71073 (57.7)	13196 (73.9)	11793 (69.5)	10968 (65.1)	9517 (60.2)	4039 (57.2)	6635 (49.7)	8077 (43.9)	6848 (40.8)	<.001



Extra – Analysis Results

	<20%	20-40%	41-60%	61-80%	81-100%	P-value
Readmission 7 day	0.8 (0.6, 1)	0.5 (0.3, 0.8)	0.5 (0.4, 0.6)	0.6 (0.5, 0.8)	0.6 (0.6, 0.8)	0.200
Readmission 30 day	2.7 (2.2, 3.3)	2.5 (2, 3.1)	2.1 (1.8, 2.6)	2.4 (2, 2.8)	2.4 (2, 2.8)	0.426
ED Revisit 7 day	0.7 (0.7, 0.8)	0.6 (0.5, 0.8)	0.6 (0.4, 0.9)	0.7 (0.6, 0.8)	0.7 (0.6, 0.8)	0.701
ED Revisit 30 days	3.1 (2.7, 3.6)	2.8 (2.5, 3.3)	2.8 (2.3, 3.4)	2.7 (2.5, 3)	2.9 (2.6, 3.3)	0.812
LOS	1.4 (1.3, 1.4)	1.3 (1.2, 1.4)	1.4 (1.3, 1.5)	1.3 (1.3, 1.4)	1.3 (1.3, 1.4)	0.344



Extra – Sub Analysis Results

	Annual Hospital-Level Dex Use							
	<20%	20-40%	41-60%	61-80%	81-100%	р		
Readmission 7 day	0.7 (0.5, 1)	0.6 (0.4, 0.9)	0.4 (0.3, 0.5)	0.7 (0.6, 0.9)	0.7 (0.6, 0.8)	0.085		
Readmission 30 day	2.6 (2, 3.3)	2.6 (2.1, 3.2)	1.9 (1.6, 2.3)	2.3 (2, 2.7)	2.2 (1.9, 2.7)	0.228		
ED Revisit 7 day	0.8 (0.7, 0.9)	0.7 (0.5, 0.9)	0.7 (0.4, 1.1)	0.7 (0.6, 0.9)	0.8 (0.7, 0.9)	0.902		
ED Revisit 30 days	3.2 (2.7, 3.7)	2.9 (2.4, 3.4)	2.7 (2.2, 3.5)	2.8 (2.4, 3.3)	3 (2.6, 3.5)	0.742		
LOS	1.3 (1.2, 1.4)	1.2 (1.2, 1.3)	1.3 (1.2, 1.3)	1.2 (1.2, 1.3)	1.2 (1.1, 1.2)	0.116		

